ClinicalTrials.gg
RecruitingNCT07290790Updated Aug 11, 2026

A Prospective Multicenter Clinical Investigation Evaluating the Accuracy of the Trimline Design When Treated With SureSmile® Aligners.

An interventional study of SureSmile® Clear Aligners in Malocclusion, sponsored by Dentsply Sirona Implants and Consumables. Recruiting at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Dentsply Sirona Implants and Consumables (part of Dentsply Sirona) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a three-armed, multicenter clinical study evaluating the SureSmile clear aligner medical device. The primary objective is to confirm the safety and assess the accuracy of different tooth movements. In addition, the study will investigate and compare three different trimline designs: Scalloped, Straight, and Straight Extended.

02

Conditions studied

  • Malocclusion

Browse trials for

03

In context

Malocclusion

323 studies on the registry are indexed under Malocclusion; 85 are open to participants now.

This study's planned enrollment of 90 is above the median of 37 across 242 interventional studies indexed under Malocclusion.

Browse Malocclusion studies →

Lead sponsor

Dentsply Sirona Implants and Consumables is the lead sponsor of 36 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject willing to participate in the clinical investigation, able to understand the intent risks and benefits of the clinical investigation as well as associated time commitment and follow-ups visits.
  • Subject has signed and dated the form (ICF) .
  • Subject aged 18 years or above at time of informed consent.
  • Subject has permanent dentition (i.e., all 2nd molars).
  • Subject with a dental malocclusion, consistent with Levels 1 and 2 case complexity and within the clinical references as defined in the SureSmile Case Selection Guide.

    • Crowding or spacing must be ≤6mm present in one or both arches consistent with level 1 and 2 of case complexity.
    • Midline deviation must be ≤3 mm consistent with level 1 and 2 of case complexity.
    • Overjet must be ≤4 mm consistent with level 1 and 2 case complexity.
    • Overbite must be ≤3 mm consistent with level 1 and 2 case complexity.
    • Anterior open bite must be ≤1 mm, consistent with level 1 and 2 case complexity.
  • Intermaxillary elastics may be included within the treatment plan to support sagittal, vertical, or transverse correction within the limits defined under exclusion criteria.

Exclusion criteria

Exclusion Criteria:

  • Subjects unlikely to comply with procedures, or unlikely to come back for follow-up visits, as judged by the Investigator.
  • Subject that presents a dental malocclusion classified as level 3 case complexity, as defined in the SureSmile Case Selection Guide.
  • Subjects who have completed aligner therapy within the last 12 months or who are in active orthodontic treatment.
  • Subjects with active periodontal disease or other unresolved dental conditions such as active cavities, active periodontal disease.
  • Subjects with treatment plans requiring transverse correction requiring expansion greater than 4 mm per arch or 2 mm per quadrant, or any skeletal transverse correction.
  • Treatment plans requiring sagittal correction exceeding a half-cusp discrepancy (i.e., >½ unit) in molar or canine relationships.
  • Subjects with treatment plans require vertical correction beyond Level 1 and 2 thresholds (i.e., overbite >3 mm or anterior/posterior open bite >1 mm), or vertical elastics exceeding 3 mm.
  • TMJ (Temporo-Mandibular Join) disorders or history of headaches or migraines.
  • Participants with known history of plastic allergies.
  • Subjects with presence of skeletal discrepancies necessitating orthognathic surgery, rapid palatal expansion, other orthopedic intervention, unilateral or bilateral cross-bites, mandibular deviations in association with the diagnosed malocclusion
  • The use of TADs (Temporary Anchor Devices), plates, other fixed anchorage ancillaries or the use of functional appliances (distalizers, growth modification devices), any approach involving orthopedic or skeletal sagittal correction or the use of hybrid fixed appliances are not considered part of the scope of this clinical investigation and these subjects are not eligible.
  • Uncontrolled para-functional habits, e.g., bruxism.
  • Any other condition that would make the subject unsuitable for participation, including but not limited to:

    • Unstable psychiatric illness.
    • Recent myocardial infarction (\< 3 months*).
    • Recent cerebrovascular accident (\< 3 months*).
    • Recent cardiac-valvular prosthesis placement (\< 3 months*).
    • Hemorrhagic diathesis.
    • Severe liver dysfunction.
    • Known or suspected current .
  • Known pregnancy at the time of enrolment.
  • Previous enrolment in the present clinical investigation.
  • Involvement in the planning and conduct of the clinical investigation (applies to both Dentsply Sirona personnel and the clinical investigation site).
  • Participation in another clinical investigation that may interfere with the present clinical investigation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Scalloped trimline design

    SureSmile® Clear Aligner (Group 1) with scalloped trimline design

    Device: SureSmile® Clear Aligners

  • Experimental
    Straight trimline design

    SureSmile® Clear Aligner (Group 2) with straight trimline design

    Device: SureSmile® Clear Aligners

  • Experimental
    Extended trimline design

    SureSmile® Clear Aligner (Group 3) with extended trimline design (2 mm)

    Device: SureSmile® Clear Aligners

Interventions

  • DeviceSureSmile® Clear Aligners

    SureSmile® Clear Aligners are Custom-made (EU)/patient matched (US) medical devices made to fit appliance with different diameters and lengths to accommodate subjects with different mouth shapes and sizes. This clinical investigation consists of three different trimline designs groups: * SureSmile aligner Scallop trimline design * SureSmile aligner Straight trimline design * SureSmile aligner Straight extended trimline design All pre-treatment, treatment, and post-treatment protocols and materials used in all groups are identical, except for the type of trimline design.

06

What researchers measure

Primary outcomes

  1. Tooth movement accuracy at subject level across different movement types

    The primary objective of this clinical investigation is to provide a detailed assessment of tooth movement accuracy at subject level across different movement types. For each patient, all teeth will be evaluated in five dimensions of movement: 1. Mesiodistal translation \[mm\] 2. Buccolingual translation \[mm\] 3. Intrusive/extrusive movement \[mm\] 4. Mesiodistal angulation \[degrees\] 5. Buccolingual torque \[degrees\] Accuracy will be determined by comparing the predicted versus achieved tooth positions for 16 teeth in each subject using the formula: "Percentage of accuracy" =100 - \[(\|predicted-achieved\| / \|predicted\|) \*100\]" Subject effectiveness is the overall mean of all the collected "Percentage of accuracy" values.

    Time frame: At start of aligner treatment and at end of aligner treatment according to predetermined treatment plan (end of aligner treatment is on average 6-18 months after aligner treatment start).

Secondary outcomes

  1. Perceived comfort/pain

    Perceived comfort/pain experienced by subjects will be assessed using a Visual Analogue Scale (VAS) with a Wong Baker face.

    Time frame: Every 8 weeks from start of aligner treatment up to to end of aligner treatment according to predetermined treatment plan (on average 6-18 months). Plus every 8 weeks during refinement period, on average 8-12 weeks.

  2. SureSmile Clear Aligner Refinement rates.

    SureSmile Clear Aligner Refinement rates aim to measure the number of refinements required among three different trimline groups.

    Time frame: At end of aligner treatment according to predetermined treatment plan (end of aligner treatment is on average 6-18 months after aligner treatment start).

  3. Occurrence of Adverse Events, Adverse Device Effects, and Device Deficiencies during the clinical investigation.

    Adverse Events, Adverse Device Effects, and Device Deficiencies spontaneously reported, and collection at each clinical investigation visit.

    Time frame: From Day 0 up to Retainer Delivery Visit, on average 18 months post Day 0.

07

Study locations

3 of 6 sites recruiting
  • Costanzo Orthodontics
    Fresno, California 93720, United States
    Recruiting
  • Center for Orthodontic Excellence
    Princeton Junction, New Jersey 08550, United States
    Not yet recruiting
  • J Chichetti PLLC 2
    Huntersville, North Carolina 28078, United States
    Recruiting
  • Brush 365 Dental
    Frisco, Texas 75035, United States
    Recruiting
  • Clinica Dental Ortiz Puigpelat
    Barcelona, 08028, Spain
    Not yet recruiting
  • The Sanford
    Bexleyheath, DA6 8AA, United Kingdom
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2027, 23 months after the start.

Of 163 interventional studies with no phase under Malocclusion, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 32. This study's planned 23 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Dec 18, 2025
StartActual
Jan 29, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Feb 1, 2028
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07290790
Responsible party
Sponsor
First posted
Dec 18, 2025
Start date
Jan 29, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
Aug 11, 2026

Study contacts

Freja Freedman
Contact
freja.freedman@dentsplysirona.com
+46 702107415
Ulrika Bonander
Contact
ulrika.bonander@dentsplysirona.com
+46 706440844

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion